CARFLIEVA 60 mg contains Carfilzomib, a second-generation proteasome inhibitor. It selectively and irreversibly inhibits the 20S proteasome, leading to accumulation of abnormal proteins and apoptosis of malignant plasma cells. It is mainly used in multiple myeloma.

Carfilzomib is indicated for treatment of:

1. Relapsed or Refractory Multiple Myeloma
    – As monotherapy or
    – In combination with dexamethasone, lenalidomide, or daratumumab

Common side effects:

•  Fatigue

•  Anemia, thrombocytopenia

•  Nausea, diarrhea

•  Fever

Cardiopulmonary effects:

•  Dyspnea

•  Hypertension

•  Heart failure (serious)

Other serious effects:

•  Renal toxicity

•  Hepatotoxicity

•  Infusion-related reactions

•  Thrombotic microangiopathy (rare)

Close monitoring of cardiac function, BP, CBC, renal & liver function is required.

Dosage is based on body surface area (BSA) and regimen.

Common regimen (Kyprolis-based):

•  Cycle 1:
    – Day 1 & 2: 20 mg/m² IV

•  If tolerated:
    – Increase to 27 mg/m² or up to 56 mg/m² on Days 8, 9, 15, 16

60 mg vial allows flexible dosing for higher-dose regimens.


NOTE: This medicine should be taken only under a doctor’s supervision.